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Available online 18 January 2017Background: There remains uncertainty regarding whether a single fasting glucose measurement is sufﬁcient to
predict risk of adverse perinatal outcomes.
Methods:We included 12,594 pregnantwomenwho underwent a 75-g oral glucose-tolerance test (OGTT) at 22–
28 weeks' gestation in the Born in Guangzhou Cohort Study, China. Outcomes were large for gestational age
(LGA) baby, cesarean section, and spontaneous preterm birth.We calculated the area under the receiver operator
characteristic curves (AUCs) to assess the capacity of OGTT glucose values to predict adverse outcomes, and com-
pared the AUCs of different components of OGTT.
Results: 1325 women had a LGA baby (10.5%). Glucose measurements were linearly associated with LGA, with
strongest associations for fasting glucose (odds ratio 1.37, 95% conﬁdence interval 1.30–1.45). Weaker associa-
tionswere observed for cesarean section and spontaneous preterm birth. Fasting glucose have a comparable dis-
criminative power for prediction of LGA to the combination of fasting, 1 h, and 2 h glucose values during OGTT
(AUCs, 0.611 vs. 0.614, P = 0.166). The LGA risk was consistently increased in women with abnormal fasting
glucose (≥5.1 mmol/l), irrespective of 1 h or 2 h glucose levels.
Conclusions: A single fasting glucose measurement performs comparably to 75-g OGTT in predicting risk of
having a LGA baby.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Fasting plasma glucose
Oral glucose-tolerance test
Large for gestational age
Cesarean section
Spontaneous preterm birth1. Introduction
Large for gestational age (LGA), deﬁned as a birthweight ≥ 90th per-
centile for gestational age, is the predominant adverse outcome associ-
ated with maternal hyperglycemia (Langer et al., 2005; Metzger et al.,
2008). LGA is the main factor underlying birth trauma and preterm
birth, as well as obstructed labor, that leads to cesarean delivery (Kc et
al., 2015; Zhang et al., 2008). Long-term effects of LGA for the offspringohort Study and Department
d Children’s Medical Center,
a.
ohort StudyandDepartment of
ical Center, GuangzhouMedical
ia), qxiu0161@163.com
B.V. This is an open access article uinclude obesity, themetabolic syndrome, type 2 diabetes and insulin re-
sistance (Damm et al., 2016).
In clinical practice, the main aim of gestational diabetes mellitus
(GDM) treatment is to control glucose metabolism and thus reducing
fetal macrosomia and obstetric complications as well as to prevent obe-
sity in the offspring. Treatment of GDM is supposed to decrease the risk
of fetalmacrosomia (Crowther et al., 2005; Landon et al., 2009). In 2010,
the International Association of the Diabetes and Pregnancy Study
Groups (IADPSG) recommended new criteria for GDM diagnosis,
based on odds ratios of abnormal birth weight, cord C-peptide and per-
cent body fat observed in the Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) study (Metzger et al., 2008), with the primary aim
of prevention of obesity risk among high-risk offspring. The test criteria
include relatively lower cut-off values and single abnormal of a fasting,
1 h or 2 h glucosemeasuredby anuniversal, single stage screening of 2 h
75-g oral glucose-tolerance test (OGTT) is adequate tomake a diagnosis,
which consequently increased the prevalence of GDM in many coun-
tries including China adopted this criteria (Cundy et al., 2014). Althoughnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The recruitment and participation ﬂowchart.
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sis, it has many disadvantages of not reproducible, time-consuming and
fairly demanding for both the pregnant women and the laboratory
(Davidson, 2002; Hanna and Peters, 2002). Given the uncertainty of
the utility of each glucose measurement in the prediction of fetal
macrosomia and the signiﬁcant resource implications of the IADPSG
criteria, there remains controversy regarding this screeningmethodolo-
gy for identiﬁcation of macrosomia risk during pregnancy (Kalter-
Leibovici et al., 2012).
In the setting of developing countries with limited resource, the
screening and management of high-risk population may be more im-
portant and cost-effective than GDM diagnosis. Fasting plasma glucose
(FPG) provides a cheap, acceptable reliable, reproducible alternative
GDM screening method to the OGTT for the last three decades
(Mortensen et al., 1985; Zhu et al., 2013), with renewed attention fol-
lowing introduction of the IADPSG criteria. Early studies suggested
that FPG had signiﬁcantly higher predictive value for LGA in comparison
to post-load glucose, independent of maternal BMI and 2 h glucose
value (Disse et al., 2013; Legardeur et al., 2014). A recent systematic re-
view also found that fasting glucose concentration has stronger associa-
tions with LGA than post-load glucose concentration (Farrar et al.,
2016). FPG performance has been largely determined by utility to
GDM detection using speciﬁc criteria, with limited information regard-
ingprediction of adverse pregnancy outcomes (Agarwal, 2016). Howev-
er, the U.S. Preventive Services Task Force has suggested that the gold-
standard for GDM screening tests, should include an acceptable, agreed
set of relevant pregnancy outcomes (Donovan et al., 2013). There re-
mains uncertainty regarding whether a single FPG measurement is suf-
ﬁcient for prediction of increased risk of adverse perinatal outcomes.
The aim of the study was to evaluate the performance of single FPG
measurement versus a complete 75-g OGTT for screeningwomen at in-
creased risk of perinatal outcomes, primarily abnormal birthweight, in a
large contemporary cohort of Chinese pregnant women.
2. Methods
2.1. Study Design and Participants
The Born in Guangzhou Cohort Study (BIGCS) is a prospective birth
cohort study conducted in the GuangzhouWomen and Children's Med-
ical Center (GWCMC), China. This hospital serves women and children
in Guangzhou city, including approximately 16,000 deliveries per year.
We recruited pregnant women who (1) resided in Guangzhou, (2)
intended to remain in Guangzhou with their child for at least 3 years,
and (3) intended to receive routine antenatal care and deliver at the
GWCMC. 15,198 women participated in BIGCS and delivered between
February 2012 and June 2016 were eligible for the present analysis.
We excluded thosewomenwith pre-pregnancy diabetes or chronic hy-
pertension, multiple pregnancies, termination of pregnancy or missing
OGTT or delivery data. Fig. 1 shows the participants' ﬂowchart for this
study. Thewomenwhomet the criteria of diabetesmellitus in pregnan-
cy (n = 70, 0.5%, i.e. fasting plasma glucose ≥ 7.0 mmol/l or 2 h 75 g
post-load plasma glucose ≥ 11.1 mmol/l (WHO, 2013)) were included
for analysis.
At recruitment, all eligible participants provided written informed
consent, and completed a self-administered comprehensive question-
naire to obtain demographic, socio-economic, environmental, lifestyle,
occupational and medical information. The study protocol was ap-
proved by GWCMC Ethics Approval Board.
2.2. Oral Glucose-Tolerance Test
Eligible participants underwent a standard 2 h 75 g OGTT between
22 and 28 weeks' gestation.Women were given instructions by doctors
to follow theWHO procedures to fast overnight (8–14 h) before testing.
Before drawing blood, the nurses conﬁrmed with the pregnant womenthat they have an overnight fasting. 2 ml blood samples were collected
at fasting, 1 h, and 2 h after thewomen receipt of 300mlwater inwhich
75 g of anhydrous glucose dissolved, respectively, using NaF/EDTA
tubes. Blood samples were stored at room temperature before 3 time-
points of glucose were all drew. Once the samples were sent to the lab-
oratory, they were centrifuged and plasma glucose was measured im-
mediately by a hexokinase method using Beckman Coulter AU5800
automatic analyzer (Beckman Coulter®, California, United States). The
laboratory has achieved ISO15189 certiﬁcation by China National Ac-
creditation Service for Conformity Assessment. At each batch, quality
control plasma was set to calculate the coefﬁcients of variation. The co-
efﬁcients of variation for low and high value were 1.63% and 1.43%, re-
spectively. If values are outside 3SD, recalibration and retest were
performed to conﬁrm the result. The glucose concentration of OGTT
and testing date were extracted from the GWCMC Laboratory Informa-
tion System. Women whose prenatal 75-g OGTT results met or
exceeded at least one threshold of the IADPSG criteria (FPG ≥5.1mmol/l,
1 h glucose ≥ 10.0mmol/l, and 2 h glucose ≥ 8.5mmol/l) including those
have overt diabetes in pregnancy received routine clinical intervention
by diet and exercise therapy. After diet control for 3 to 5 days, the
women with GDM were asked to self-monitored and recorded
preprandrial blood glucose (30 min before breakfast/lunch/dinner),
postprandial blood glucose (30 min after breakfast/lunch/dinner), and
nocturnal blood glucose at home every day. Of these women, those
with FPG ≥ 5.3 mmol/l or 2 h postprandial glucose was ≥6.7 mmol/l
after diet therapy were prescribed insulin or glyburide in addition to
diet and exercise (Obstetrics Subgroup and Group of Pregnancy with
Diabetes Mellitus, 2014). Obstetrical complications such as pregnancy
hypertension disease, hydramnios, and infection were monitored by
the obstetricians.
2.3. Perinatal Outcomes
Themain outcomes included birthweight (continuous), birthweight
Z score (continuous), LGA, cesarean section (C-section), and spontane-
ous preterm birth (SPTB). Birthweight and other information, including
gestational age at delivery, mode of delivery, newborn gender, and
pregnancy complications were obtained from medical records using
the hospital-based information system. Birth weight was measured by
GWCMC midwives immediately after delivery. Birthweight Z scores
were calculated using a local population-based birth weight reference
(He et al., 2014). LGA was deﬁned as a birthweight larger than the
90th percentile for gestational age by gender, based on the same birth
weight reference (He et al., 2014). Gestational age was estimated from
ultrasound examination during the ﬁrst- or second-trimester. SPTB
was deﬁned as birth following spontaneous preterm labor and/or
Table 1
Study participant characteristics (n= 12,889).
Characteristics No. of total (%) Mean ± SD
Maternal characteristic
Age, years 12,889 (100.0) 29.1 ± 3.4
Plasma glucose, mmol/l
Fasting 12,889 (100.0) 4.3 ± 0.4
1 h 12,889 (100.0) 7.7 ± 1.7
2 h 12,889 (100.0) 6.6 ± 1.4
Gestation week at time of OGTT, week 12,889 (100.0) 24.5 ± 1.6
Income (RMB), %
b1500 1204 (9.8)
1500–4500 3647 (29.7)
4501–9000 5248 (42.7)
≥9001 2179 (17.8)
Education, %
Middle school or below 1205 (9.4)
College 3230 (25.1)
Undergraduate 6864 (53.3)
Postgraduate 1590 (12.3)
Pre-pregnancy body mass index, kg/m2 12,636 (98.0) 20.4 ± 2.7
Height, cm 12,751 (98.9) 160.0 ± 4.9
Family history of diabetes 1273 (10.2)
Smoking during pregnancy, % 62 (0.5)
Passive smoking during pregnancy, % 3695 (29.5)
Parity at enrollment ≥ 1, % 1768 (13.9)
Use of assisted reproduction technology, % 421 (3.4)
Newborn characteristic
Gender
Boy, % 6683 (52.5)
Girl, % 6039 (47.5)
SD= standard deviation; OGTT = oral glucose-tolerance test.
Table 2
The prevalence of perinatal outcomes (n= 12,889).
Characteristic or outcome No. of participants (%) Mean ± SD
Obstetrical outcomes
Cesarean delivery, % 4383 (34.8)
Newborn outcomes
Gestational age at delivery, week 12,888 (100.0) 38.8 ± 1.5
Preterm birth, % 630 (4.9)
Spontaneous preterm birth, % 426 (3.4)
Birth weight, g 12,678 (98.4) 3191.6 ± 425.6
Birth weight Z score 12,678 (98.4) 0.1 ± 1.0
Birth weight for gestational age, %
SGA 920 (7.3)
AGA 10,349 (82.2)
LGA 1325 (10.5)
SD = standard deviation; AGA = appropriate for gestational age was deﬁned as
10th ≤ birth weight ≤ 90th percentile for gestational age; SGA = small for gestational
agewas deﬁned as birth weight b 10th percentile for gestational age; LGA= large for ges-
tational age was deﬁned as birth weight N 90th percentile for gestational age on the basis
of local population-based birth weight reference.
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irrespective of mode of delivery (vaginal, cesarean section) obtained
from medical records and independently conﬁrmed by two
pediatricians.
2.4. Statistical Analysis
Descriptive statistics were reported for continuous (mean, SD) and
categorical (number, percentage) variables respectively. To examine as-
sociations between maternal glycemia and perinatal outcomes, each
glucosemeasurementwas considered as a continuous variable.Multiple
linear and logistic regressions were used to evaluate continuous (birth
weight, birth weight Z score) and categorical measures (LGA, C-section,
and SPTB), respectively. Odds ratios (ORs) and regression coefﬁcients
were calculated for a 1-SD increase in each fasting, 1 h, and 2 h glucose
measurement. All models were adjusted for maternal age, maternal ed-
ucation, maternal income, maternal pre-pregnancy body mass index
(BMI), height, parity,maternal smoking or passive smoke exposure dur-
ing pregnancy, family history of diabetes, use of assisted reproduction
technology, baby gender and gestational age at OGTT date. To explore
differences in associations in diverse social economic status, we did
stratiﬁed analysis bymaternal income and education aswell as included
an interaction term betweenmaternal income or education and glucose
measurement in the model.
We used receiver operating characteristic (ROC) analyses to assess
the predictive capacity of FPG, 1 h, 2 h glucose for the categorical perina-
tal outcomes speciﬁed. To explore additional predictive power of post-
load glucose values, we added 1 h and/or 2 h glucose values to the
FPG model, calculating the respective area under the curve (AUC) mea-
sures. The areas under correlated ROC curves of different glucose mea-
surements were compared using a non-parameteric approach
developed by DeLong (Delong et al., 1988).
To explore the inﬂuence of gestational week of undertaking OGTT,
we undertook a sensitivity analysis by repeating analyses restricted to
women who underwent OGTT between 24 and 28 weeks' gestation.
To evaluate the treatment effect, we performed a sensitivity analysis re-
stricted towomenwithout GDM,whowere untreated, andwe also con-
ducted an analysis that added the GDM status as a proxy of use of
treatment (yes or no) in the model for adjustment. To explore the risk
of perinatal outcomes identiﬁed by each abnormal glucose measure-
ment based on IADPSG criteria, we categorizedwomen into eightmutu-
ally exclusive categories according to 2 h 75-g OGTT result (Fig. 3). The
prevalence of perinatal outcomes in each group and the adjusted ORs
were calculated, using no-GDM as the reference group.
All analyses were performed using SAS 9.2 software (SAS Institute,
Cary, NC, USA). A P value b 0.05 was considered to indicate statistical
signiﬁcance.
3. Results
A total of 15,198 pregnant women recruited to the cohort study de-
livered between Feb 2012 and Jun 2016 (Fig. 1). We excluded 2309
women for the following reasons: withdrawal (n= 623), diagnosis of
pre-pregnancy hypertension (n = 44), diabetes (n = 28), multiple
pregnancy (n = 319), termination of pregnancy (n = 143), stillbirth
(n = 27), missing delivery data (n = 227), and missing OGTT (n =
898). We included information obtained from 12,889 mother-newborn
pairs in the analyses. There were no signiﬁcant differences in
birthweight or gestational age between those women included in the
ﬁnal analysis (n = 12,889) and those who had missing OGTT results
(n = 898). The characteristics between women who dropped out or
missing OGTT results and delivery data and womenwhowere included
in the analysis were only statistical different in parity (Appendix Table
1).
Participant baseline characteristics and outcome measures are sum-
marized in Tables 1 and 2. The mean FPG, 1 h, and 2 h plasma glucoselevels were 4.3 mmol/l, 7.7 mmol/l, and 6.6 mmol/l, respectively.
Using the IADPSG criteria, there were 1779 (N = 12,889, 13.8%)
women diagnosedwith GDMwho received a subsequent diet and exer-
cise advice (425with FPG ≥ 5.1mmol/l, 1354with FPG b 5.1mmol/l and
abnormal post-load glucose). Eleven (11/12,889, 0.1%)womenwent on
to receive insulin therapy. The overall prevalence of LGA, C-section, and
SPTB was 10.5% (1325/12,594), 34.8% (4383/12,614), and 3.4% (426/
12,655), respectively (Table 2).
Table 3 shows the association betweenmaternal glucose and perina-
tal outcomes. For birthweight and birthweight Z score, the coefﬁcients
for 1-SD increase in all OGTT measures glucose were signiﬁcant.
Among the categorical outcomes, the associations were strongest for
LGA (ORs for each 1-SD increase in glucose level range, 1.17 to 1.37).
For cesarean section and spontaneous preterm birth, the associations
were weaker. The associations between fasting glucose and
birthweight, birthweight Z score, and LGA were strongest for fasting
glucose as compared to both post-load glucose concentrations. No sta-
tistical evidence of an interaction of glucose measurements (fasting,
Table 3
Adjusted coefﬁcients or ORs for associations between maternal glucose (continuous variables) and perinatal outcomes.
Outcomes Total no. (no. with outcome)
Plasma glucose level
Fasting At 1 h At 2 h
Adjusted coefﬁcients or ORs
(95% CI)a
Adjusted coefﬁcients or ORs
(95% CI)a Adjusted coefﬁcients or ORs (95% CI)a
Entire cohort
Birthweight, coefﬁcients 12,678 42.01 (34.55, 49.48) 18.95 (11.38, 26.52) 13.32 (5.71, 20.94)
Birthweight Z score, coefﬁcients 12,678 0.12 (0.10, 0.14) 0.08 (0.06, 0.10) 0.07 (0.05, 0.08)
Large for gestational age, ORs 12,594 (1325) 1.37 (1.30, 1.45) 1.24 (1.16, 1.31) 1.17 (1.11, 1.25)
Cesarean section, ORs 12,614 (4383) 1.12 (1.08, 1.17) 1.03 (0.99, 1.07) 1.04 (1.00, 1.09)
Spontaneous preterm birth, ORs 12,655 (426) 1.05 (0.95, 1.16) 1.20 (1.09, 1.33) 1.21 (1.10, 1.33)
Abbreviations: CI, conﬁdence interval, ORs, odd ratios.
a Regression coefﬁcients or ORs were for an increase in the glucose level of 1 SD (0.4mmol/l for the fasting glucose level, 1.7 mmol/l for the 1 h glucose level, and 1.4mmol/l for the 2 h
glucose level). Adjusted for maternal age, income, educational level, smoking during pregnancy, second hand smoking exposure during pregnancy, pre-pregnancy BMI, height, family his-
tory of diabetes, gender, parity, assisted reproductive technology, gestational week at the OGTT.
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Tables 2 and 3). Results of analyses restricted to women underwent
OGTT at 24–28 gestation's weeks did not change signiﬁcantly (Appen-
dix Table 4). Whenwe restricted to the womenwithout a GDM diagno-
sis, we found that the association between fasting glucose and
birthweight or LGA is still stronger than post-load glucose in non-
GDM women (Appendix Table 5). When we used the GDM status as a
proxy of use of treatment (yes or no) and included in model for adjust-
ment, the results were similar to ﬁndings when the analysis was re-
stricted to women without GDM (Appendix Table 6).
The ROC curves evaluating the performance of OGTT glucose mea-
surements for predicting perinatal outcomes are shown in Fig. 2. For
LGA, the AUC of FPG was signiﬁcantly higher than 1 h (0.611 vs. 0.566,
P b 0.0001) and 2 h (0.611 vs. 0.551, P b 0.0001) glucose measurements
and did not signiﬁcantly increase after adding 1 h and 2 h measure-
ments to the FPG predictive model. The AUCs for other two outcomes
were all smaller than LGA. Similar results were foundwhen the analysis
restricted to women underwent OGTT at 24–28 gestation's weeks (Ap-
pendix Fig. 1) and women without GDM (Appendix Fig. 2). Although
the P value for the comparison of FPG with OGTT measurements in
women without GDM is b0.05, the conﬁdence intervals was rather
close and the signiﬁcance is more likely to be caused by large sample
size.
To assess the contribution of each glucose measure in identifying
risk of outcomes, we classiﬁed participants into eight categories accord-
ing to IADPSG diagnostic criteria. Fig. 3 and Appendix Table 7 showed
the respective GDM prevalence and adjusted OR (used no-GDM as ref-
erence) for outcome measures by diagnostic category. LGA prevalence
was signiﬁcantly higher among women with abnormal FPG
(≥5.1 mmol), irrespective of 1 h or 2 h post-load glucose levels (preva-
lence range 19.68%–26.67%, ORs range 1.72–2.62 in women with i-IFG,
IFG + IGT1, IFG + IGT2, or IFG + IGT1 + 2). Among women with
FPG b 5.1 mmol, the prevalence of LGA was relatively low, even for
those abnormal 1 h or/and 2 h glucose level (prevalence 10.1%,13.8%,
8.9%, and 8.4% for no-GDM, i-IGT1, i-IGT2, i-IGT1 + 2 group; ORs
[95%CI] were 1.27[0.92, 1.75] for i-IGT1, 0.87[0.62,1.20] for i-IGT2 and
0.77[0.53,1.11] for i-IGT1 + 2). Similar results were observed for cesare-
an section although there was no signiﬁcant association for i-IFG,
IFG + IGT1, IFG + IGT2, or IFG + IGT1 + 2. Women with two abnormal
glucose measures seem to have a higher risk of SPTB.
4. Discussion
In this large-scale prospective cohort study,we observed continuous
associations of fasting, 1 h and 2 h post-load glucose with LGA. Weaker
associations were observed for cesarean section and spontaneous pre-
term birth. FPG have a comparable discriminative power for prediction
of LGA to the combination of fasting, 1 h, and 2 h glucose values during
OGTT. These ﬁndings are broadly consistent with those reported in acomparable Asian cohort study and recent systematic review (Aris et
al., 2014; Farrar et al., 2016).
Numerous studies examining the FPG performance for screening
GDM included the patients selected by clinical history or positive glu-
cose challenge test, which was a biased population leading to improve-
ment of FPG performance and limitation of the generation to entire
population (Perucchini et al., 1999). The previous studies that explored
FPG performance used GDM diagnosed by speciﬁc criteria as the gold
standard rather than used pregnancy outcomes (Agarwal et al., 2011;
Poomalar and Rangaswamy, 2013). The few studies comparing FPGper-
formance to post-load glucose based on pregnancy outcomes reported
comparable AUCs for post-load glucose in prediction of LGA to our
study (0.578 for 1 h, 0.573 for 2 h in Trujillo et al.'s study (Trujillo et
al., 2015); 0.549 for 2 h in Disse et al.'s study (Disse et al., 2013)). The
AUCs for fasting glucose in prediction of LGA in present study was
higher than that reported by Trujillo et al. (n= 4077, AUC: 0.553) and
lower than that reported by Disse et al. (n = 75, AUC: 0.783). In line
with our results, Disse et al. found that FPG was the only glucose value
signiﬁcantly predictive of LGA babies (Disse et al., 2013). In a sub-cohort
of HAPO study, the Kalter-Leibovici et al. found that one-third of
IADPSG-positive women had low risk of fetal macrosomia and they de-
velopedanalternative screeningmethod largelybyuseof FPG≥89mg/dl
(Kalter-Leibovici et al., 2012).
The lack of additional predictive power provided by inclusion of
post-load glucoses in the FPG predictive model for LGA suggests that
FPG alone could provide adequate diagnostic utility to identify those
pregnant women with a higher risk of LGA. In the HAPO study women
with IADPSG-positive FPG had the highest prevalenc of LGA (19.5%),
compared to those with IADPSG-positive 1- and/or 2 h glucose level
and normal FPG (12.6%) and IADPSG-negative women (8.2%)
(Coustan et al., 2010). The result partially supports our ﬁnding that iso-
lated abnormal 1 h and/or 2 h glucose have lower risk of LGA than ab-
normal FPG. Based on these ﬁndings, we suggest that screening for
GDM in the purpose of screening and management of women at high
risk of delivering an LGA baby can use a single FPG measurement in-
steadof a universal one step of OGTT, especially in the areaswith limited
health resource. It is well established that FPG and post-load glucose
levels reﬂect metabolic alterations among women with GDM and this
relationship will not be observed from fasting glucose values in isola-
tion. However, the aim of universal GDM screening is to inform risk
stratiﬁcation for LGA and fasting glucose measurements provides im-
proved acceptability and cost-effectiveness.
Insulin has been proven to be the most important growth hormone
(Eslamian et al., 2013) that promotes maternal hypertriglyceridemia
during pregnancy (Butte, 2000), alters lipid transport to the fetus
(Radaelli et al., 2009) and up-regulates other placental nutrient trans-
port pathways (Brett et al., 2014). Previous studies revealed that basal
insulin resistance (usually with higher level of insulin) plays the most
crucial role on elevation of FPG level, whereas the decrease in glucose-
Fig. 2. Receiver operating characteristic curves (ROCs) of fasting, 1 h and 2 h glucose measurements for prediction of perinatal outcomes. *The AUCs for 1 h or/and 2 h glucose were
signiﬁcantly different from fasting glucose (P b 0.05).
288 S. Shen et al. / EBioMedicine 16 (2017) 284–291induced insulin secretion (insulin decreased) is themost important fac-
tor contributing to elevation of 2 h glucose level in the general popula-
tion (Hanefeld et al., 2003). Some authors also reported that women
with elevated FPG during pregnancy have higher fasting insulin levels
and primarily hepatic insulin resistance and are more likely to require
insulin therapy than those with isolated elevated post-load glucose
levels (Disse et al., 2013; Zamzami, 2007). These studies suggest thatelevated FPG exerts a greater effect on fetal growth through increase
of maternal insulin level than elevated post-load glucose levels.
The study had several strengths; ﬁrstly, most previous studies that
have explored the performance of FPG for screening GDM were based
on various criteria for GDM diagnosis as opposed to pregnancy out-
comes (Agarwal, 2016). We conducted a large-scale prospective cohort
study to assess the utility of a single FPG screening test as an alternative
Fig. 3. Prevalence of perinatal outcomes by IADPSG criteria (glucose level). ‘Case’ indicates the number of outcome cases in corresponding category of glucose levels. ‘Total’ indicates the
total number of pregnant women in corresponding category of glucose levels. ‘%’ indicates the prevalence of outcomes in corresponding category of glucose levels. Non-GDM: no glucose
impairment; i-IFG: isolated impaired fasting glucose if FPG ≥ 5.1 mmol/l and both 1 h glucose b 10.0 mmol/l and 2 h glucose b 8.5 mmol/l; i-IGT1: single isolated impaired 1 h glucose
tolerance if 1 h glucose ≥ 10.0 mmol/l and both 2 h glucose b 8.5 mmol/l and FPG b 5.1 mmol/l; i-IGT2: single isolated impaired 2 h glucose tolerance if 2 h glucose ≥ 8.5 mmol/l and
both 1 h glucose b 10.0 mmol/l and FPG b 5.1 mmol/l; i-IGT1 + 2: double-isolated impaired glucose tolerance if both 1 h glucose ≥ 10.0 mmol/l and 2 h glucose ≥ 8.5 mmol/l but
FPG b 5.1 mmol/l; IFG + IGT1: combined IFG and IGT1 if FPG ≥ 5.1 mmol/l and 1 h glucose ≥ 10.0 mmol/l but 2 h glucose b 8.5 mmol/l; IFG + IGT2: combined IFG and IGT2 if
FPG ≥ 5.1 mmol/l and 2 h glucose ≥ 8.5 mmol/l but 1 h glucose b 10.0 mmol/l; IFG + IGT1 + 2: combined IFG and IGT1 + 2 if FPG ≥ 5.1 mmol/l and 1 h glucose ≥ 10.0 mmol/l and
2 h ≥ 8.5 mmol/l.
289S. Shen et al. / EBioMedicine 16 (2017) 284–291method for GDM diagnosis, targeted at identiﬁcation of increased LGA
risk. Secondly, our study provides high quality, accurate information
on outcome measures, reducing misclassiﬁcation and measurement
error. Thirdly, we adjusted for a comprehensive range of potential con-
founding factors in our analyses, allowing us to assess the independent
effect of maternal hyperglycemia exposure from co-existing maternal
and fetal exposures. In the present study, we did not exclude the
women who met the criteria of diabetes in pregnancy because one of
the aims was to analyse the association of maternal hyperglycemia in
pregnancy with adverse pregnancy outcomes as well as the clinical
managements for diabetes mellitus in pregnancy and gestational diabe-
tes was similar in China (Obstetrics Subgroup and Group of Pregnancy
with Diabetes Mellitus, 2014). Finally, the doctors gave the women an
instruction for OGTT to follow the standard procedures recommendedby WHO and the nurses who drew the blood conﬁrmed the overnight
fasting of the pregnant women before OGTT, which largely reduced
the inadequate fasting.
Our study had some limitations. Firstly, we did not collect cord-
blood C-peptide concentrations and newborn fat mass, which had
been used to develop IADPSG criteria. In human studies, strong associa-
tions of LGA and neonatal adiposity with fetal hyperinsulinemia
were observed, independent of confounding factors (Langer et al.,
2005). Although increased neonatal adiposity is one of the indicators
of abnormal fetal development in intrauterine exposure to maternal
hyperglycaemia, long-term effects of neonatal adiposity remain unde-
termined (Logan et al., 2016). Moreover, we considered that the other
two surrogate markers were of less relevance for clinical practice. The
consistency in observed association between FPG and both outcome
290 S. Shen et al. / EBioMedicine 16 (2017) 284–291measures to those reported in previous studies indicate the relevance of
our endpoints to be comparable to those obtained in the HAPO study
(Metzger et al., 2008). Secondly, in our study, women with GDM diag-
nosis routinely receive diet and exercise intervention, with only a
small proportion of women received insulin therapy. Two randomized
control trials (RCTs) have indicated that treatment of mild GDM could
reduce birth weight (Crowther et al., 2005; Landon et al., 2009). Treat-
ment of GDMmay be expected to lower the prevalence of adverse out-
comes and the natural effect ofmaternal hyperglycemia on fetal growth.
Whereas, the sensitivity ROC analysis in women without GDM, who
were untreated, suggests that single FPG still have comparable discrim-
inative power for predicting LGA in untreated women in Chinese popu-
lation The sensitivity analysis adjusting for GDM treatment also showed
similar associations of OGTT measurements with LGA to those in non-
GDMwomen. Admittedly, further studies are needed to determine the
optimal threshold of FPG for high risk screening. Thirdly, BIGCS partici-
pants were recruited at a tertiary care centre and are likely to have
higher socio-economic status which may limit generalisability of our
ﬁndings to other settings. We did not however observe any signiﬁcant
interactions betweenmaternal income or educational level and glucose
measures on LGA, suggesting the effects of glucose levels were similar
across populations with different socio-economic status. In the present
study, about 12% of participants were lost to follow-up or had missing
data. We found baseline characteristics of these women and women
who were included in the analysis not to be statistical different except
for parity. Exclusion of these women would not change the results
signiﬁcantly.
To conclude,we report that 1 h and/or 2 h plasma glucose levels con-
tribute little to LGA prediction in the present analyses. We propose that
a single FPG screening can provide a valid measurement to identify
higher risk of LGA in Chinese population. It willmarkedly reduce labora-
tory burden, numbers of intervention, rates of early-term birth and C-
section, and neonates requiring special care, especially in China where
medical resources were limited in many areas. When generalizing our
ﬁndings to other settings, the difference (or overlap) in distribution of
abnormal fasting, 1 h or 2 h between populations should be considered.
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